▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Celcuity (NASDAQ: CELC)

$54.60

(9.3%)

$4.64

Price as of August 28, 2025, 4:00 p.m. ET

Celcuity Return vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
CELC	+229.11%	+849.57%	+56.82%	+250%
S&P	+15.21%	+84.76%	+13.06%	+159%

Celcuity Company Info

Celcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

News & Analysis

Featured Article

Celcuity Q2 Results Highlight Cash Surge

Motley Fool Markets Team | Aug 14, 2025

Featured Article

Celcuity Expenses Jump 81 Percent

Motley Fool Markets Team | Aug 14, 2025

Why Celcuity Stock Is Crashing Today

Keith Speights | Jun 29, 2021

The clinical-stage biotech announced the pricing of a secondary stock offering.

Valuation

Earnings Transcripts

Celcuity (CELC) Q2 2025 Earnings Call Transcript

None

Motley Fool Transcribing | Aug 14, 2025

Celcuity Inc. (CELC) Q4 2018 Earnings Conference Call Transcript

CELC earnings call for the period ending December 31, 2018.

Motley Fool Transcribers | Feb 26, 2019

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services